GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adimmune Corp (TPE:4142) » Definitions » Cyclically Adjusted Revenue per Share

Adimmune (TPE:4142) Cyclically Adjusted Revenue per Share : NT$4.08 (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Adimmune Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Adimmune's adjusted revenue per share for the three months ended in Dec. 2024 was NT$1.293. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$4.08 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Adimmune's average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Adimmune was 12.20% per year. The lowest was 8.90% per year. And the median was 10.55% per year.

As of today (2025-05-10), Adimmune's current stock price is NT$18.50. Adimmune's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was NT$4.08. Adimmune's Cyclically Adjusted PS Ratio of today is 4.53.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Adimmune was 31.38. The lowest was 4.36. And the median was 10.79.


Adimmune Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Adimmune's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adimmune Cyclically Adjusted Revenue per Share Chart

Adimmune Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.76 3.16 3.63 3.90 4.08

Adimmune Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.90 3.98 3.85 4.03 4.08

Competitive Comparison of Adimmune's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Adimmune's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adimmune's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adimmune's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Adimmune's Cyclically Adjusted PS Ratio falls into.


;
;

Adimmune Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adimmune's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=1.293/133.1571*133.1571
=1.293

Current CPI (Dec. 2024) = 133.1571.

Adimmune Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.112 99.621 0.150
201506 0.110 100.684 0.145
201509 0.437 100.392 0.580
201512 0.514 99.792 0.686
201603 0.183 100.470 0.243
201606 0.453 101.688 0.593
201609 0.623 101.861 0.814
201612 1.201 101.863 1.570
201703 0.305 102.862 0.395
201706 0.201 103.349 0.259
201709 0.920 104.136 1.176
201712 0.853 104.011 1.092
201803 0.284 105.290 0.359
201806 0.131 106.317 0.164
201809 1.570 106.507 1.963
201812 1.626 105.998 2.043
201903 0.254 107.251 0.315
201906 0.379 108.070 0.467
201909 1.421 108.329 1.747
201912 1.729 108.420 2.123
202003 0.988 108.902 1.208
202006 0.155 108.767 0.190
202009 1.464 109.815 1.775
202012 1.894 109.897 2.295
202103 0.016 111.754 0.019
202106 0.205 114.631 0.238
202109 1.732 115.734 1.993
202112 2.199 117.630 2.489
202203 0.123 121.301 0.135
202206 1.280 125.017 1.363
202209 2.540 125.227 2.701
202212 1.376 125.222 1.463
202303 0.403 127.348 0.421
202306 0.195 128.729 0.202
202309 2.325 129.860 2.384
202312 1.327 129.419 1.365
202403 0.104 131.776 0.105
202406 0.189 132.554 0.190
202409 2.092 133.029 2.094
202412 1.293 133.157 1.293

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Adimmune  (TPE:4142) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Adimmune's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=18.50/4.08
=4.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Adimmune was 31.38. The lowest was 4.36. And the median was 10.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Adimmune Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Adimmune's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Adimmune Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adimmune Corp (TPE:4142) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
Tanxing Road, No. 3, Sector 1, Tanzi District, Taichung, TWN, 427003
Adimmune Corp is a Taiwan-based company. It is engaged in the development, manufacture, and distribution of vaccines and other biological products. Its pipeline consists of products like AdimFlu-S (QIS) which is a vaccine intended for use in the prevention of influenza, and TetraFlu among others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the USA, China, and other regions.

Adimmune Headlines

No Headlines